- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined b ...

Exhibit 99.1 Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined by execution, advancing SER ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No. ...

HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST. A live webcast of the fireside chat style presentation will be accessible to registered attendees at this link. An ...

U.S. stock futures declined on Friday following Thursday’s declines. Futures of the major benchmark indices were lower.Meanwhile, the 10-year Treasury bond yielded 4.28%, and the two-year bond was at 3.83%. The CME Group's FedWatch tool‘s projections show markets pricing a 93.8% likelihood of the Federal Reserve leaving the current interest rates unchanged in its April meeting. IndexPerformance (+/-)Dow Jones-0.08%S&P 500-0.12%Nasdaq 100-0.28%Russell 2000-0.18%Stocks In FocusFedEx FedEx Corp. (NYSE:FDX) jum ...

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price– - Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027 - - Proceeds to s ...

Core Insights - Serina Therapeutics has initiated dosing for the first patient in its Phase 1b registrational clinical trial for SER-252, targeting advanced Parkinson's disease [1][3][4] - The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients whose symptoms are not adequately managed by existing therapies [2][8] - The company expects to advance to Cohort 2 following a blinded evaluation by the Safety Monitoring Committee in the third quarter of 2026 [1][2] Company Overview - Serina Therapeutics is a clinical-stage biotechnology firm focused on developing drug candidates for neurological diseases using its proprietary POZ Platform [5] - The POZ Platform enhances drug efficacy and safety profiles across various modalities, including small molecules and RNA-based therapeutics [6] - The company is headquartered in Huntsville, Alabama, and collaborates with Parkinson's Australia and Neuroscience Trials Australia for patient enrollment [3][5] Product Details - SER-252 is an investigational therapy designed to provide continuous dopaminergic stimulation, potentially reducing levodopa-related motor complications in Parkinson's disease [8] - The POZ technology utilized in SER-252 aims to improve pharmacokinetic profiles, addressing issues like toxicity and short half-life associated with existing treatments [6][8] - The company has established partnerships, including a non-exclusive license agreement with Pfizer for the use of its POZ polymer technology in lipid nanoparticle drug delivery [7]

Core Viewpoint - Serina Therapeutics has enrolled its first patient in a Phase 1b registrational trial for SER-252, targeting advanced Parkinson's disease, which represents a significant operational milestone for the company [1][3]. Group 1: Trial Details - The Phase 1b study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients whose symptoms are not adequately managed by existing therapies [2]. - Dosing for the trial is expected to begin in the current quarter, aligning with previously disclosed timelines [2]. Group 2: Company Operations - The company has established a strong operational presence in Australia, collaborating with Parkinson's disease specialists and advocacy groups to facilitate patient enrollment [3]. - Serina has received FDA alignment on its registrational development strategy under a 505(b)(2) NDA pathway, focusing on executing the trial and generating clinical data for patients with significant unmet medical needs [3]. Group 3: Technology and Product Information - Serina Therapeutics is developing SER-252, an investigational apomorphine therapy utilizing the POZ platform, designed to provide continuous dopaminergic stimulation, potentially reducing levodopa-related motor complications in Parkinson's disease [7]. - The POZ platform technology is based on a synthetic polymer that enhances drug loading control and release precision, aiming to improve the efficacy and safety profiles of various therapeutic modalities [5]. Group 4: Future Plans - The company intends to explore additional applications of the POZ platform through out-licensing, co-development, or partnerships, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery formulations [6].

Core Insights - Serina Therapeutics' CEO, Steven Ledger, will present at a webinar discussing the impact of new FDA initiatives on drug development and investor expectations in the life sciences sector [1][2] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ [5] - The POZ Platform™ aims to enhance the efficacy and safety profiles of various drug modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [5] Event Details - The webinar titled "Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" is scheduled for February 4, 2026, at 8:30 AM Pacific / 11:30 AM Eastern [1] - Participants can submit questions for the CEO before and during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - TechCreate Group Ltd. (TCGL) is up 99% at $205.71 - VivoSim Labs, Inc. (VIVS) is up 74% at $2.96 - La Rosa Holdings Corp. (LRHC) is up 55% at $4.66 - Sandisk Corporation (SNDK) is up 23% at $668.13 - Springview Holdings Ltd (SPHL) is up 19% at $4.76 - BUUU Group Limited (BUUU) is up 16% at $10.86 - Deckers Outdoor Corporation (DECK) is up 11% at $111.64 - Lumentum Holdings Inc. (LITE) is up 10% at $419.58 - Chanson International Holding (CHSN) is up 10% at $2.15 - Century Therapeutics, Inc. (IPSC) is up 9% at $2.20 [3] Premarket Losers - Kaixin Holdings (KXIN) is down 43% at $5.70 - Brand Engagement Network, Inc. (BNAI) is down 32% at $35.56 - PennyMac Financial Services, Inc. (PFSI) is down 21% at $117.50 - Schneider National, Inc. (SNDR) is down 19% at $24.05 - Moolec Science SA (MLEC) is down 19% at $5.23 - Nuwellis, Inc. (NUWE) is down 18% at $3.43 - Digital Currency X Technology Inc. (DCX) is down 16% at $3.44 - Serina Therapeutics, Inc. (SER) is down 15% at $3.03 - Namib Minerals (NAMM) is down 11% at $5.00 - ZeroStack Corp. (ZSTK) is down 6% at $11.00 [4]